Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase II Trial of Dasatinib in Subjects with Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

 


A Phase II Trial of Dasatinib in Subjects with Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation


Trial Focus

All Cancers

Objective

         This is a clinical trial of dasatinib that will be administered by mouth, which is investigational.

IRB Protocol #

12-1625

Trial Status

Archived

Principle Investigator

ROBERT DOEBELE

Sponsor

Bristol-Myers Squibb

Contact

NIKKI AYODEJI at (720)848-0701 or NIKKI.AYODEJI@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last as long as your cancer is not progressing, and you are not experiencing any unacceptable side effects. A follow up period will consist of phone contact and possible clinic visits. // Eligibility criteria include but are not limited to 18 years or older with cancer and have a certain cell mutation.Eligibility criteria include but are not limited to 18 years or older with cancer and have a certain cell mutation.